These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32951521)

  • 1. Outcomes with enoxaparin dose reductions during thrombocytopenia in patients with hematopoietic stem cell transplantation (HSCT).
    Lam J; Tavares E; Luk SO
    J Oncol Pharm Pract; 2021 Sep; 27(6):1364-1370. PubMed ID: 32951521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
    Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
    Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.
    Mantha S; Miao Y; Wills J; Parameswaran R; Soff GA
    J Thromb Thrombolysis; 2017 May; 43(4):514-518. PubMed ID: 28205078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
    Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy.
    Hart K; Andrick B; Grassi S; Manikowski J; Graham J
    Ann Pharmacother; 2021 Sep; 55(9):1120-1126. PubMed ID: 33455432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
    ; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
    JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
    Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
    Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
    Trujillo-Santos J; Bergmann JF; Bortoluzzi C; López-Reyes R; Giorgi-Pierfranceschi M; López-Sáez JB; Ferrazzi P; Bascuñana J; Suriñach JM; Monreal M
    J Thromb Haemost; 2017 Mar; 15(3):429-438. PubMed ID: 28120516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: which dose regimen should be preferred?
    Weiss A; Brose S; Ploetze K; Matschke K
    Clin Hemorheol Microcirc; 2013 Jan; 54(3):249-58. PubMed ID: 23648452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients.
    Montero Ruiz E; Baldominos Utrilla G; López Álvarez J; Santolaya Perrin R
    Thromb Res; 2011 Nov; 128(5):440-5. PubMed ID: 21880352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
    Walker CK; Sandmann EA; Horyna TJ; Gales MA
    Ann Pharmacother; 2017 Apr; 51(4):323-331. PubMed ID: 28228055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
    Hammerstingl C; Omran H;
    Thromb Haemost; 2009 Jun; 101(6):1085-90. PubMed ID: 19492151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation.
    Martens KL; Amos CI; Hernandez CR; Kebriaei P; da Costa WL; Basom R; Davis C; Kesten M; Carrier M; Garcia DA; Lee SJ; Li A
    Am J Hematol; 2021 Sep; 96(9):1137-1146. PubMed ID: 34097772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients.
    Dybdahl D; Walliser G; Pershing M; Collins C; Robinson D
    Clin Med Insights Blood Disord; 2019; 12():1179545X19863814. PubMed ID: 31360075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients.
    Fuller K; Malecki S; Anselmo L; Borrego ME; Jakeman B; Burnett A
    Ann Pharmacother; 2018 Mar; 52(3):257-262. PubMed ID: 29025276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.
    Campbell PM; Ippoliti C; Parmar S
    J Oncol Pharm Pract; 2017 Apr; 23(3):220-225. PubMed ID: 26854266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
    Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
    Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.